BUSINESS BRIEFING

Times Wire Reports

Amgen Inc. said its cancer drug Vectibix was effective for advanced colon cancer patients as a second-line therapy, a finding consistent with results released Aug. 6 for the therapy as an initial treatment.

A study found that Vectibix "significantly improved" the time before symptoms worsened in advanced colon cancer patients with a certain gene mutation, the Thousand Oaks company said.

Copyright © 2019, Los Angeles Times
EDITION: California | U.S. & World
53°